Press Releases and Events

PRESS RELEASES

Press Release | November 10, 2022

Crinetics Announces November 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | October 13, 2022

Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly

READ MORE
Press Release | October 10, 2022

Crinetics Announces October 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | October 6, 2022

Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism

READ MORE
Press Release | October 3, 2022

Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer

READ MORE
Press Release | September 12, 2022

Crinetics Announces September 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | September 8, 2022

Crinetics Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

READ MORE
Press Release | September 6, 2022

New Long-Term Safety and Efficacy Data Presented with Paltusotine in Participants Living with Acromegaly

READ MORE
Press Release | September 2, 2022

New Long-Term Safety and Efficacy Data for Paltusotine to be Presented at CBEM

READ MORE
Press Release | August 12, 2022

Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

READ MORE
13 / 25